DNMT1 has also been implicated functionally in PCa phenotypic plasticity, suggesting that targeting DNMT1 activity and the aberrant DNA methylation it produces is a potential therapeutic strategy for treating NEPC [229,230]. This evidence concerns the gene DNMT1 and posterior cortical atrophy.